ALX Oncology

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Funding reportedLast round: Post ipo equity

BiopharmaSan Francisco, United States

What company datasets say ALX Oncology raised

Funding, as reported

Reported in all$329Min dollars

Rounds6

Last roundPost ipo equity

Last round dateOct 2023

Investors listed12

From ALX Oncology's own website: 2 on the team.

Investors who name them

Each firm lists ALX Oncology on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put ALX Oncology in front of investors. Or tell us what we have wrong.